Stablecoin Development Corp

The company focuses on participation in blockchain networks and the deployment of operating digital assets, following a strategic business realignment. Its ongoing digital asset operations involve tokens such as SKY, USDS, and USDT under the oversight of an established Digital Asset Strategy Advisory Committee alongside executive management. Historically, the business engaged in commercializing healthcare and wellness products, including eye care products under the Avenova brand, wound care treatments such as Neutrophase, and skincare lines through Dermadoctor and PhaseOne Health. These legacy medical and consumer health assets were subsequently divested or classified as discontinued operations, shifting the primary organizational focus toward digital technology systems, network participation, and digital asset strategies.

The company maintains its principal corporate headquarters and administrative office space in Emeryville, California. Its corporate tax and administrative footprint includes registrations across domestic jurisdictions, specifically California, New York, South Carolina, New Jersey, and Florida. Beyond its California headquarters, the text reports no retail stores, research laboratories, or international operational facilities.

Summary of the business section of Stablecoin Development's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, on a consolidated basis, we had a total of 4 employees, 2 of whom were full-time employees and 2 who were part-time employees.”